Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Post by digger144on Jul 26, 2012 5:52pm
490 Views
Post# 20156838

Added to my Position..

Added to my Position..

Bought an additional 20,000 shares @ $.82.

Current Position:  70,000 shares @ $.85.

Yes...as any investment there are risks...but...I believe the Brigus Team is headed in the right direction!

Execution is the word...let's go Team!

If this "thing" does not double by the end of the year...then...I was wrong...a triple is not out of the question...in my opinion.

By the way...the Preliminary Economic Assessment regarding the Contact & 147 Zones is no doubt very robust...should be released shortly...they will soon get Daniel on it!

Digger144

P.S.  We must understand the moves that are being made...the addition of Daniel Racine and furthermore his acceptance is speaking loudly...the market will pick up on it!

         There are most definitely plans in the works...you can bet on it!

          I am trying to figure out exactly what is going on...I have some ideas but I just cannot put my "finger on it".

 

Bullboard Posts